Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV aflibercept in wAMD with suboptimal anti-VEGF-A response
2013-000848-26Phase 4Completed
- Sponsor
- Barcelona Macula Foundation
- Start
- Jun 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in exudative macular degeneration, sponsored by Barcelona Macula Foundation. Primary endpoint: Anatomical response on OCT at week 12. Started Jun 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2013-000848-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000848-26.